The protective effect by the medical timing of Valsartan-160mg in hypertensive CKD patients with proteinuria

The protective effect by the medical timing of Valsartan-160mg in hypertensive CKD patients with proteinuria - The protective effect by the medical timing of Valsartan-160mg in hypertensive CKD patients with proteinuria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007369

Enrollment

Registered

2012-04-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive patients with chronic kidney disease

Interventions

Group 1: administer the change of Valsartan from the standard dose of ARB. ( Take 1 tablet in the morning) Group 2: administer the change of Valsartan from the standard dose of ARB. ( Take 1 table

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients with proteinuria (more than 0.3g/g Cr) 2. In cases that systolic BP is over 130mmHg and diastolic BP is over 80mmHg who administer standard dose of ARB. The standard dose of ARB are as below. Valsartan 80mg, Losartan 50mg, Candesartan 8mg, Terumisartan 40mg, Olmesartan 20mg

Exclusion criteria

Exclusion criteria: 1. systolic BP is over 180mmHg, or diastolic BP is over 110mmHg 2. In case of severe hepatic injuries 3. nephrotic syndrome 4. the patients with pregnant or possibly pregnant 5. in case with contraindication of valsartan

Design outcomes

Primary

Measure	Time frame
Levels of urinary protein after 12 and 24 weeks	—

Secondary

Measure	Time frame
Clinic Blood pressure Home Blood pressure Ambulatory Blood pressure Estimation glomerulus filtration (eGFR) Serum potassium, serum creatinine Harmful phenomenon will be analyzed after 12 and 24 wekks	—

Countries

Japan

Contacts

Public ContactKatsuhiko Asanuma

Juntendo University Faculty of Medicine Department of Internal Medicine, Division of Nephrology

03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026